N/A
N=89
PET Scan and CT Scan in Evaluating Response in Patients Undergoing Radiofrequency Ablation for Lung Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Bottom Line
View on ClinicalTrials.gov: NCT00382252 ↗Enrolled (actual)
89
Serious AEs
2.3%
Results posted
Mar 2022
Primary outcome: Primary: Percentage of True Positive Plus True Negative Patients — 40.79 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- computed tomography (Procedure); positron emission tomography (Procedure); radiofrequency ablation (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Institut Bergonié
- Primary completion
- Dec 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of True Positive Plus True Negative Patients |
40.79 | — |
| SECONDARY Percentage of True Positive Patients |
100 | — |
| SECONDARY Percentage of True Negative Patients |
31.82 | — |
Summary
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Diagnostic procedures, such as PET scan and CT scan, may help doctors measure the patient's response to treatment.
PURPOSE: This clinical trial is studying PET scan and CT scan to see how well they work in evaluating response to treatment in patients undergoing radiofrequency ablation for lung metastases.
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed cancer
- Radiologically suspected pulmonary metastases
- May be confirmed histologically or by specific markers
- Less than 6 lesions
- Lesions 3) at the level of lesions to be treated
- Lesions must not be attached to or next to major mediastinal structures
- Radiofrequency ablation planned as treatment
PATIENT CHARACTERISTICS:
- Life expectancy > 6 months
- No uncontrolled medical condition, including any of the following:
- Psychiatric condition
- Infection
- Coronary insufficiency
- New York Heart Association class III-IV heart disease
- No other serious condition
- No contraindication to general anesthesia
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
- At least 30 days since prior participation in an investigational study
- At least 30 days since prior chemotherapy
- No other concurrent investigational agents
Data sourced from ClinicalTrials.gov (NCT00382252). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.